JMP Securities Downgrades Enanta Pharma To Market Perform

Analysts at JMP Securities downgraded Enanta Pharmaceuticals ENTA from “market outperform” to “market perform” and removed the price target of $50. Enanta Pharma shares have surged 145.97% over the past 52 weeks, while the S&P 500 index has gained 21.67% in the same period. Enanta Pharma's shares gained 1.23% to close at $42.75 on Thursday.